Breaking News
Wyeth is now a part of Pfizer Inc. The merger of local Wyeth and Pfizer entities may be pending in various jurisdictions and is subject to completion of various local legal and regulatory obligations. To learn more, please visit www.pfizer.com.

Health Care Professionals Log In

Sign up for TORISEL Updates

Gain access to additional
content on the TORISEL Web
site and receive updates.
You'll also get free, unlimited
access to:

  • The 5 minute Clinical Consult
    2009
  • Epocrates® Online Premium Reference
  • A.D.A.M. QuickSheets
Torisel Banner

Reprint Library

Get reprints of the following articles:

NOTE: In order to download reprints, you must be registered and signed in as a health care professional at Wyeth.com. If you are not yet registered, Register Now.

  • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    Hudes G, Carducci M, Tomczak P, et al. N Engl J Med. 2007;356:2271-2281.
  • Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma.
    Mekhail TM, Abou-Jawde RM, BouMerhi G, et al. J Clin Oncol. 2005;23:832-841.
  • Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.
    Motzer RJ, Bacik J, Murphy BA, et al. J Clin Oncol. 2002;20:289-296.

Patient Education Materials

Give your patients and their caregivers information about renal cell carcinoma and TORISEL.

Contact Wyeth About TORISEL

 

242252-01